Finally, as additional analogues of 8, hybrid molecules were designed by combining some of the structural features shown to confer PA-PB1 inhibitory activity. 9, 13, 15 Among the planned molecules, the positional isomers 36 and 37 (Table 1) were synthesized by merging the 1,2,4triazolopyrimidine nucleus with the cycloheptathiophene-3-carboxamide core that characterizes the previous hit 7 (Figure 1 ). The two hybrid molecules were aligned to the pharmacophore, obtaining a good similarity both for polar and hydrophobic regions (Figure 3) , with the 1,2,4-triazolopyrimidine nucleus being oriented in the lower hydrophobic region of the pharmacophore, in an opposite way to compounds 28 and 31 (Figure 2) , to gain the better alignment of the polar regions.
CHEMISTRY
The synthesis of all the target compounds was accomplished through a carbodiimide-mediated coupling reaction by reacting the 2-amino and 2-carboxylic acid 1,2,4-triazolo [1,5-a] pyrimidine synthones with the appropriate benzoyl chlorides and amines, respectively. Although the triazolopyrimidines chemistry has been widely explored, 26 very few reports were focused on the synthesis of 2-amino and 2-carboxylic acid 1,2,4-triazolo[1,5-a]-pyrimidine derivatives. Thus, the synthesis of the synthones 38, 41, 42, 45, and 47 required an in-depth study aimed to determine the best synthetic pathway and conditions to obtain the desired positional isomers in high yield. In Schemes 1 and 2, selected procedures among those reported in the literature or appositely setup are shown, while a thorough comparative study will be reported in due course. Synthone 38 27 was prepared as reported in the literature, by reacting 3,5-diamino-1,2,4-triazole with benzylideneacetone in DMF at reflux (Scheme 1). The same reaction was applied to prepare synthone 41 28 (Scheme 1), but adding Ac2O to the reaction mixture after the condensation completion, in order to protect the amino group in the successive oxidation step. The oxidation of compound 39 performed with N-bromosuccinimide (NBS) gave intermediate 40, which after acid hydrolysis gave the desired synthone 41. An analogous three-step procedure was planned to synthesize the unknown synthone 42 by reacting 3,5-diamino-1,2,4-triazole with phenyl 1-propenyl ketone in DMF at reflux (Scheme 1). Fortunately, the reaction furnished directly the aromatic compound 42. The reaction of synthones 38, 41, and 42 with the appropriate benzoyl chloride, performed in pyridine, furnished the target compounds 8 and 11−33. All the 4,7dihydrotriazolopyrimidine derivatives were purified by crystallization from EtOH, since the compounds undergwent an extensive transformation to a main unidentified product when column chromatography was used as purification method.
Similarly to the preparation of synthones 41 and 42, the synthesis of triazolopyrimidine-2carboxylic acids 45 and 47 was accomplished by reacting ethyl 5-amino-1,2,4-triazole-3carboxylate 29 with benzylideneacetone and phenyl 1-propenyl ketone, respectively, in DMF at reflux (Scheme 2). Using 3-amino-1,2,4-triazole-5-carboxylic acid as starting material, the reaction furnished only decarboxylated triazolopyrimidine scaffolds. In agreement with what has been described above, the reaction with benzylideneacetone gave the saturated compound 43, which was then oxidized with NBS in EtOH at reflux in the presence of AcONa, to give 44. On the other hand, 
RESULTS AND DISCUSSION
Hit compound 8 (compound 31 in ref 18 ), previously tested as provided from the vendor, was synthesized and retested, giving comparable results in terms of PA−PB1 interaction inhibitory activity (IC50 = 153 μM) and maintaining the same profile of antiviral activity and cytotoxicity. The in-house synthesized 8 was then used as comparative compound in all successive studies.
The whole set of derivatives was evaluated for the ability to inhibit the physical interaction between PA and PB1 subunits by ELISA, including the PB1(1−15)−Tat peptide 30 as a positive control. In parallel, for all the synthesized compounds, the antiviral activity was tested by plaque reduction assay (PRA) in Mardin−Darby canine kidney (MDCK) cells infected with a reference FluA virus, the A/PR/8/34 strain. Ribavirin (RBV), a known broad-spectrum inhibitor of RNA viruses polymerase, 31 was included as a positive control of inhibition, exhibiting EC50 = 10 μM. To exclude that the observed antiviral activities could be due to toxic effects in the target cells, all the synthesized compounds were tested by MTT assays in two cell lines, i.e., MDCK and human embryonic kidney (HEK) 293T. The antiviral activity and toxicity data for the tested compounds are reported in Table 1 .
As to what impacts the modifications made on the phenyl ring at the C-2 position of the dihydrotriazolopyrimidine core, the shifting of the methoxy group from para (compound 8) to meta (compound 12) and ortho (compound 11) positions decreased the PA−PB1 interaction inhibitory activity. The same behavior was observed for the fluoro analogues 13−15. Among the various parasubstituted derivatives, compounds 16−18 were more active than hit 8, but only for p-propoxy derivative 16 did the ability to inhibit the PA−PB1 interaction perfectly translate to anti-Flu activity in a cellular context, with EC50 = 47 μM. On the other hand, compounds 19, 21, and 25 inhibited the viral growth but did not interfere with the PA−PB1 complex formation. For these compounds, all characterized by a bulky substituent at the C-2 position, an alternative mechanism of action might be postulated, or simply the antiviral activity could be due to a certain toxicity.
The aromatic triazolopyrimidine compounds 28−30 were all devoid of activity against the PA−PB1 interaction, thus making them less suitable than their 4,7-dihydrotriazolopyrimidine counterparts (compounds 26, 8, and 16). The Fingerprints for Ligands and Proteins (FLAP) binding poses evaluated in silico for compound 26 and its aromatic analogue 28 were very similar, with the heterocyclic and heteroaromatic cores interacting with W706 ( Figure 4 ). However, compound 28, due to its more linear shape, appears to match the hydrophobic field generated by W706 less efficiently than 26, and this difference might be responsible for the lower activity of the aromatic analogues.
When in the aromatic scaffold the methyl and phenyl groups were interchanged (compounds 31−33), the PA−PB1 inhibitory activity was restored, with compound 31 exhibiting a good IC50 value of 26 μM, perfectly comparable to that obtained in inhibiting the vral replication (EC50 = 25 μM). The ability of compound 31 to interfere with PA−PB1 complex markedly decreased when the C-2 amide linker was inverted, as in compound 35, which however maintained the antiviral activity.
Definitely, the most exciting result in this study was achieved with the hybrid molecules 36 The other hybrid molecule 37, although endowed with a lower ability to interfere with PA−PB1 complex formation (IC50 = 28 μM), emerged as the best in inhibiting the viral growth (EC50 = 8.0 μM). Structurally, the two molecules differ only in opposite positions of the substituents on the triazolopyrimidine core, with the 5-methyl group and 7-phenyl ring being the most suitable substitution pattern for PA−PB1 inhibition. To evaluate possible differences in the binding mode of compounds 36 and 37, their FLAP binding poses were analyzed ( Figure 5 ). Both compounds orient the triazolopyrimidine ring toward the W706 residue of PA that defines the first hydrophobic pocket, to give an efficient π−π stacking. In addition, compound 37, due to its elongated shape, seems to be able to locate the phenyl ring into the second hydrophobic pocket of PA, defined by P710 and L666, and the cycloheptathiophene ring into the third hydrophobic pocket defined by L640, V636, and W619, according to the cavity description by Liu and co-workers33 ( Figure 5A ).
This binding mode is comparable to that previously observed for compound 9 24 (data not shown).
On the other hand, compound 36 seems to be shifted toward the opposite side of the cavity, thus matching only the first hydrophobic region ( Figure 5B ). Changing the perspective ( Figure 5C ,D), we can notice that, based on this model, the shift for compound 36 is due to a favored H-bonding between its 2-amidic carbonyl group and Q408, according to the FLAP GRID fields analysis. In our previous studies, the interactions with W706 and with the second hydrophobic pocket in proximity of P710 were usually detected for the most active compounds; the achievement of more active derivatives designed to optimize these hydrophobic interactions validated the hypothesis about this favorable binding mode. 22 On the contrary, compound 36 emerges as the first compound within our series of derivatives for which an interaction with Q408 seems to occur. Although these findings need to be further investigated, it is known that Q408 is a key residue for PB1 binding through Hbonding, and this might be the reason for the surprisingly potent activity. The interaction with Q408 has been recently hypothesized also for other PA−PB1 inhibitors, although their inhibitory effect was lower than that of compound 36. 34 From the comparison of the spatial dispositions of the two amidic carbonyl groups in compounds 36 and 37 in Figures 5 with the ones in Figure 3 , minor differences emerge. These differences are induced by the interaction with the protein structure, and this is a demonstration that combining a pharmacophore approach with a structure-based approach, when possible, represents a suitable strategy for pharmacophore refinement.
Compounds 16, 31, 36, and 37, endowed with the best ability to inhibit both PA−PB1 interaction and viral growth, were further characterized. First, we investigated their ability to interfere with the catalytic activity of FluA RdRP in a cellular context by minireplicon assays performed in transfected HEK 293T cells. As shown in Table 2 , for all the compounds the ability to disrupt the PA−PB1 interaction in vitro correlated well with the polymerase inhibitory activity, with the best compounds 36 and 37 showing EC50 values of 12 and 16 μM, respectively, comparable to that of the reference compound RBV (EC50 = 18 μM). We then tested the ability of the best compound 36 to interfere with the physical interaction between PA and PB1 in a cellular context.
To this end, we investigated whether the compound could affect PA−PB1 binding in the cell cytoplasm and consequently block the intranuclear translocation of PA, which requires formation of a PA−PB1 complex, 32 while PB2 enters the cell nucleus independently. Thus, we transfected HEK 293T cells with plasmids expressing PB1, PB2, and a PA−GFP fusion protein and analyzed the intracellular localization of PA−GFP in the presence or absence of compound 36 (or DMSO as a control). As previously shown, 32 individually expressed PA−GFP was largely cytoplasmic, while coexpression of PA−GFP with PB1 and PB2 resulted in marked nuclear accumulation of PA ( Figure 6 ). Treatment of PA−PB1−PB2-coexpressing cells with compound 36 reduced PA nuclear localization, while DMSO had no effect ( Figure 6 ).
Finally, the antiviral effects of compounds 16, 31, 36, and 37 against a number of strains of FluA of both HIN1 and H3N2 subtypes, including an oseltamivir-resistant clinical isolate (A/Parma/24/09), and three strains of FluB were also evaluated ( Table 3 ). All the compounds showed an interesting antiviral activity against the whole panel of Flu strains, perfectly comparable to that measured against the A/PR/8/34 strain. Compound 37 confirmed its anti-Flu potency by exhibiting the best antiviral activity, with EC50 = 5 μM against both the FluA oseltamivir-resistant clinical isolate and Flu B/Lee/40 strain. At this stage, the absorption, distribution, metabolism, and excretion (ADME) profile was preliminarily determined to assess the drug-like properties of these new small molecules. Toward this end, for the same set of compounds, 16, 31, 36, and 37, along with the hit 8, the solubility (equilibrium solubility in phosphate buffer at pH 7.4), permeability (parallel artificial membrane permeation assay (PAMPA)), and human liver microsome (HLM) metabolic stability were experimentally determined. Concerning the solubility, compound 8 showed the highest equilibrium solubility (13 μg/mL), followed by compounds 16 and 31 (5 μg/mL) and then by compounds 36 and 37, which showed very low solubility (<1 μg/mL). Because of this issue, we could not clearly estimate the cell permeability of compound 37. Based on the PAMPA, all the tested compounds showed a medium/high permeability (data are reported in the Experimental Section) and a percentage of compound trapped into the membrane ranging from 41 to 57%, with the exception of 31, the sole compound not retained by the lipid membrane. Notably, all the studied PA−PB1 inhibitors were metabolically stable in HLM, since no metabolites were detected after 30 min exposure to cytochrome metabolism. Altogether, these studies suggested that the triazolopyrimidine-based compounds are endowed with an adequate ADME profile for a drugdiscovery phase, even though the most promising antiviral derivatives 36 and 37 suffered from low solubility. Since these hybrid molecules are made of a triazolopyrimidine core merged to a cycloheptathiophene scaffold, we hypothesize that the latter may be responsible for the low solubility. Indeed, ADME studies performed on the previous cycloheptathiophene derivatives 7 and 10 showed the same poor equilibrium solubility (<1 μg/mL) and a medium/high permeability,
although they interacted almost entirely with the lipid membrane, hampering the enrichment of the acceptor phase. Thus, although compound 36 is characterized by a promising ADME profile, further modifications of the cycloheptathiophene moiety will be required to achieve the best compromise between solubility and cell permeability.
CONCLUSIONS
The limited therapeutic options against Flu infection along with the drug resistance issue make imperative the search for next generation agents. Although the inhibition of viral polymerases is a common approach in the identification of antiviral drugs, the development of compounds able to interfere with the correct assembly of viral polymerase complexes is an innovative strategy. 35−38 In this context, we have been recently interested in the inhibition of the interaction of Flu polymerase PA−PB1 subunits by small molecules. In the present work, starting from the dihydrotriazolopyrimidine hit 8, a weak PA−PB1 interaction inhibitor with no significant anti-Flu activity, and through a hit-to-lead optimization, novel potent inhibitors endowed with a broad anti-Flu activity have been discovered. The best results were achieved with the hybrid molecules 36 and 37, obtained by combining the herein developed triazolopyrimidine and the previously explored cycloheptathiophene scaffolds. With an IC50 = 1.1 μM, compound 36 exhibits a 150-fold higher activity than hit compound 8, definitely emerging as the most potent in the scenario of the PA−PB1 small molecule inhibitors developed so far. This ability translates in a broad anti-Flu activity with no cytotoxicity. From this study, the triazolopyrimidine core emerges as very suitable to inhibit the physical interaction between PA and PB1 subunits, probably thanks to an efficient π−π staking interaction with W706 of the first hydrophobic pocket, as suggested by the FLAP poses. The computational studies also showed that the different binding mode of the various triazolopyrimidine derivatives is markedly influenced by the substituents at the C-5 and C-7 positions but mainly by the group placed at the C-2 position. While the 2-cycloheptanethiophene moiety is definitely able to ensure potent activity, a wider exploration of the C-2 position is strongly required, also to meet the need for compounds with an improved ADME profile. The design of new drug-like analogues, also based on hydrophilic interactions while decreasing unnecessary hydrophobic moieties, is also supported by the peculiar ability of the potent compound 36 to establish a very favored H-bonding with Q408.
During the final drafting of this manuscript, novel crystal structures of the influenza virus polymerase were published, 39, 40 thus opening new opportunities to refine the SBDD.
EXPERIMENTAL SECTION
Computational methods. The binding poses in the PA cavity were generated using the FLAP software (Molecular Discovery Ltd., UK; www.moldiscovery.com). Indeed, the FLAP approach 41 was previously used to identify inhibitors of the PA-PB1 complex by virtual screening 18 and proved also to be useful to design more active compounds. 22 The procedure has been extensively described elsewhere. 22 As in the previous studies, the main cavity of the crystallographic structure of a large C-terminal fragment of PA (aa 257-716) (pdb code: 3CM8) 14 was used as a template. A total of 50 conformers for each ligand were generated to mimic the compound flexibility, and the most abundant protonation state predicted of each molecule was used, as predicted by MoKa. 42 The probes used to generate the GRID Molecular Interaction Fields were H (shape), DRY (hydrophobic interactions), N1 (H-bond donor) and O (H-bond acceptor) interactions. The FLAP software was also used to align the selected compounds into the pharmacophore model. The pharmacophore generation using FLAPpharm algorithm 43 was recently described. 24 Here, the pharmacophore was used as a template to run the FLAP virtual screening module.
Chemistry. All reactions were routinely checked by TLC on silica gel 60F254 (Merck) and Reagents and solvents were purchased from common commercial suppliers and were used as such.
After extraction, organic solutions were dried over anhydrous Na2SO4, filtered, and concentrated with a Büchi rotary evaporator at reduced pressure. Yields are of purified product and were not optimized. All starting materials were commercially available unless otherwise indicated.
General procedure for carbodiimide formation (Method A).
A solution of the appropriate synthones (1.0 equiv) in pyridine was added of the suitable benzoyl chloride (2.0 equiv). The reaction mixture was maintained at room temperature until no starting material was detected by TCL. After cooling, the reaction mixture was poured into ice/water, obtaining a precipitate which was filtered and purified as described below.
Compounds 8 and 11-27 were prepared starting from synthone 38 27 through Method A and purified by crystallization by EtOH. Methyl-7-phenyl-4,7-dihydro[1,2,4]triazolo[1,5-a]pyrimidin-2-yl 
4-Methoxy

N-(5-
4-Butyl-N-(5-methyl-7-phenyl-4,7-dihydro[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)benzamide (18).
Yield, 51%. White crystals, mp 261-263 °C; 1 Methyl-7-phenyl-4,7-dihydro[1,2,4]triazolo[1,5-a]pyrimidin-2-yl Methyl-7-phenyl-4,7-dihydro[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)-4-nitrobenzamide (23) . -N-(5-methyl-7-phenyl-4,7-dihydro[1,2,4]triazolo[1,5-a] Methyl-7-phenyl-4,7-dihydro[1,2,4]triazolo[1,5-a]pyrimidin-2-yl N-(5-Methyl-7-phenyl-4,7-dihydro[1,2,4]triazolo[1,5-a]pyrimidin-2-yl) Methyl-7-phenyl-4,7-dihydro[1,2,4]triazolo[1,5-a]pyrimidin-2-yl Compounds 28-30 were prepared starting from synthone 41 28 through Method A and purified by flash chromatography eluting with CHCl3/MeOH (98:2). Methyl-7-phenyl[1,2,4]triazolo[1,5-a] Methyl-7-phenyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl N-(7-Methyl-5-phenyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl) N-(7-Methyl-5-phenyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)-4-propoxybenzamide (33) . Yield, General procedure for carbodiimide formation (Method B). To a solution of the suitable carboxylic acid (1.0 equiv) in well dry CH2Cl2, oxalyl chloride (3 equiv) was added and after 30 min DMF (2 drops) was added. After 2 h, the reaction mixture was evaporated to dryness to give a residue that was dissolved in well dry CH2Cl2 and added of the appropriate aniline (1.0 equiv) and DIPEA (1.0 equiv). After 1 h, the reaction mixture was evaporated to dryness to give a residue that was treated with ice/water to give a solid that was filtered and purified as described below.
N-(5-
N-(5-Methyl-7-phenyl-4,7-dihydro[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)biphenyl-4-
N-(5-
4-Chloro
N-(5-
Compounds 34 and 36 were prepared starting from synthone 45 through Method B and purified by flash chromatography eluting with CHCl3/MeOH (98:2) and then by crystallization by EtOH/DMF mixture. Methyl-N,5-diphenyl[1,2,4]triazolo[1,5-a] N-[3-(Aminocarbonyl)-5,6,7,8-tetrahydro-4H-cyclohepta[b]thien-2-yl]-5-methyl-7phenyl[1,2,4]triazolo[1,5-a]pyrimidine-2-carboxamide (37) . Yield, 25%. Orange crystals, mp 313 °C (dec.); 1 (45) . A mixture of 44 (0.45 g, 1.59 mmol) and NaOH (0.079 g, 1.99 mmol) in MeOH (10 mL) was refluxed for 30 min.
7-
5-Methyl-7-phenyl[1,2,4]triazolo[1,5-a]pyrimidine-2-carboxylic acid
After cooling, the reaction mixture was poured into ice/water and acidified with 2N HCl obtaining a precipitate that was filtered. The filtrate was extracted with EtOAc and the organic layers were evaporated to dryness obtaining a residue that was treated with Et2O and filtered, to give 45 (0.13 g, 32%); mp 172-174 °C; 1 The gradient elution was performed with a flow rate of 1.5 mL/min using a generic fast gradient.
After detection with DAD, the eluent entered the electrospray system using the following source settings: capillary voltage + 3.5 kV, drying gas flow (N2) 13 L/min, nebulizer pressure 60 sig, drying gas temperature 350 °C. The integral of the pseudo molecular ion intensity, [M+H]+, was acquired in single reaction monitoring mode (SRM).
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